Solid Biosciences (SLDB) Net Income towards Common Stockholders: 2016-2024
Historic Net Income towards Common Stockholders for Solid Biosciences (SLDB) over the last 9 years, with Dec 2024 value amounting to -$120.6 million.
- Solid Biosciences' Net Income towards Common Stockholders fell 84.64% to -$38.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$120.6 million, marking a year-over-year decrease of 24.19%. This contributed to the annual value of -$120.6 million for FY2024, which is 24.19% down from last year.
- According to the latest figures from FY2024, Solid Biosciences' Net Income towards Common Stockholders is -$120.6 million, which was down 24.19% from -$97.1 million recorded in FY2023.
- In the past 5 years, Solid Biosciences' Net Income towards Common Stockholders registered a high of -$72.2 million during FY2021, and its lowest value of -$120.6 million during FY2024.
- In the last 3 years, Solid Biosciences' Net Income towards Common Stockholders had a median value of -$103.8 million in 2022 and averaged -$107.2 million.
- As far as peak fluctuations go, Solid Biosciences' Net Income towards Common Stockholders climbed by 24.68% in 2020, and later slumped by 43.84% in 2022.
- Solid Biosciences' Net Income towards Common Stockholders (Yearly) stood at -$88.3 million in 2020, then increased by 18.24% to -$72.2 million in 2021, then plummeted by 43.84% to -$103.8 million in 2022, then climbed by 6.48% to -$97.1 million in 2023, then declined by 24.19% to -$120.6 million in 2024.